|
Synonyms: Bysanti® | VHX-896 | VHX896
milsaperidone is an approved drug
Compound class:
Synthetic organic
Comment: Milsaperidone (VHX-896) is a prodrug of the dopamine D2 receptor and serotonin 5-HT2A receptor antagonist iloperidone.
|
|
|||||||||||||||||||||||||||||||||||
| No information available. |
Summary of Clinical Use ![]() |
| Milsaperidone (VHX-896) was progressed to clinical studies to determine safety and efficacy as an oral atypical antipsychotic, for major depressive disorder, schizophrenia and bipolar I disorder. The US FDA approved milsaperidone in early 2026, to treat schizophrenia or manic or mixed episodes associated with bipolar I disorder [1]. |
| Clinical Trials | |||||
| Clinical Trial ID | Title | Type | Source | Comment | References |
| NCT06830044 | Evaluation of Efficacy and Safety of Milsaperidone as Adjunctive Therapy in Patients With Major Depressive Disorder | Phase 3 Interventional | Vanda Pharmaceuticals | ||